Sana Biotechnology Inc vs Zoom Video Communications, Inc. — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while Zoom Video Communications, Inc. trades at $97.74 (market cap $27.62B). The key difference: Zoom Video Communications, Inc. is far larger — about 33× Sana Biotechnology Inc's market cap, and Zoom Video Communications, Inc. is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Zoom Video Communications, Inc. for 92 Days on average.
| SANA | ZM | |
|---|---|---|
Market Cap | $836.71M | $27.62B |
Volume | 4,507,444 | 3,913,188 |
Sector | Health | Technology |
52-Week High | $5.92 | $111.88 |
52-Week Low | $2.68 | $72.72 |
Typical Hold Time | 23 Days | 92 Days |
Enterprise Value | $749.96M | $20.43B |
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Zoom (ZM) trades at $94.67, down 0.11% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong profitability with a net income margin of 65.19% and ROE of 32.14% for 2025. Recent earnings beat expectations in Q1 and Q2 2026, while Q4 2025 missed. Analyst consensus price target is $118.08, implying significant upside. News highlights include AI product launches and board appointments, supporting growth initiatives.
The outlook for ZM is positive given its robust fundamentals, earnings momentum, and Wall Street's bullish stance. Key opportunities include AI-driven revenue growth and strategic investments. Risks involve competitive pressures, execution challenges, and market volatility. The stock presents a compelling case for growth investors, though careful monitoring of quarterly performance is advised.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →